Volume : 13, Issue : 07, July – 2026

Title:

FORMULATION AND EVALUATION OF DICLOFENAC SODIUM SUSTAINED RELEASE TABLET

Authors :

Zeba Naaz, Dr. Abdul Sayeed, Dr. Syed Areefulla Hussainy, Dr. Faizan Sayeed

Abstract :

The present study involves the formulation and evaluation of Diclofenac Sodium sustained release tablets using various polymers in different ratios to achieve prolonged drug release and enhanced patient compliance. Polymers such as Hydroxypropyl Methylcellulose (HPMC), Ethyl Cellulose (EC), and Sodium carboxy methyl cellulose were employed as release-retarding agents. A total of nine formulations (DS1 to DS9) were prepared by the direct compression method and evaluated for pre-compression and post-compression parameters including angle of repose, bulk density, tablet hardness, friability, weight variation, drug content, and in vitro drug release studies.
All the evaluated parameters were found to be within acceptable limits as per Indian Pharmacopoeia (IP) standards, indicating the suitability of the formulation process. Among the nine formulations, DS4 was identified as the optimized formulation, as it demonstrated a sustained drug release of 99.57% over 12 hours, following controlled release kinetics. The optimized formulation exhibited consistent matrix integrity and desirable drug release profile.
The study concludes that a suitable combination of polymers in appropriate ratios can effectively sustain the release of Diclofenac Sodium, making it a promising approach for once-daily oral administration.
Keywords: Diclofenac Sodium, HPMC, Ethyl Cellulose, and Sodium carboxy methyl cellulose
y

Cite This Article:

Please cite this article in press Zeba Naaz et al., Formulation And Evaluation Of Diclofenac Sodium Sustained Release Tablet, Indo Am. J. P. Sci, 2026; 13(07).

REFERENCES:

1. Jain KK. Drug delivery systems. 1st edition. Switzerland: Humana Press; 2008. P. 1-51.Reddy KR., Mutalik S, Reddy S. AAPS Pharm. Sci. Tech.2003; 4: 19. 121-125.
2. Chien YW. Novel drug delivery system. 2nd edition revised and expanded. New York: Informa health care; 2009. P. 1-50.
3. Jantzen GM, Robinson JR. Sustained and Controlled- Release Drug Delivery Systems Modern Pharmaceutics, 4thed; 2003; 121: 501-502.
4. Salsa T, Veiga F. Drug Develop. Ind Pharm. 1997; 23: 931.
5. Gwen MJ, Joseph RR, In Banker GS and Rhodes CT, Ed. Modern Pharmaceutics, 3rdEd Marcel Dekker Inc. New York. 1996; 72: 575.
6. Jantzen GM, Robinson JR, Sustained and controlled-release drug delivery systems, in Banker GS, Rhodes CT (Eds.) Modern Pharmaceutics, 3rd Ed, Revised and Expanded, Drugs and the Pharmaceutical Sciences., Marcell Dekker, Inc. NewYork. 1995; 72: 575-609.
7. Lee BJ, Ryu SG, Cui JH, Drug Dev. Ind.Pharm.1999; 25: 493-501.
8. Vidyadhara S, Rao PR, Prasad JA. Indian J Pharm Sci. 2004; 66: 188-192.
9. Bogner RH. Bioavailability and bioequivalence of extended-release oral dosage forms. US Pharmacist. 1997; 22: 3–12.
10. Rogers JD, Kwan KC. Pharmacokinetic requirements for controlled-release dosage forms. In: John Urquhart, ed. Controlled-release Pharmaceuticals. Academy of Pharmaceutical Sciences. American Pharmaceutical Association. 1979: 95–119.
11. Madan PL. Sustained-release drug delivery systems, part II: Preformulation considerations. Pharm Manu fact. 1985; 2: 41–45.
12. Wani MS, Controlled Release System-A Review, 2008; 6 1: 56-62.